表皮生长因子受体(EGFR)是表皮生长因子基因(erbB)家族的一员,在许多上皮性肿瘤中,EGFR可以被异常活化。受体与配体结合后可以通过作用于细胞信号传导、细胞增殖、凋亡调控以及血管生成而对肿瘤的发生和增殖起作用。早在20多年前,Mendelsohn等[1]就提出EGFR可以作为肿瘤治疗的 Epidermal growth factor receptor (EGFR) is a member of the erbB family of epidermal growth factors that can be aberrantly activated in many epithelial tumors. Receptor and ligand binding can play a role in tumorigenesis and proliferation by acting on cell signaling, cell proliferation, apoptosis regulation and angiogenesis. As early as 20 years ago, Mendelsohn et al [1] proposed EGFR can be treated as a tumor